Highlights CureVac N.V.

Equities

CVAC

NL0015436031

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
3.89 ^USD	+3.18%		+5.42%	-7.60%

May. 28	CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	MT
May. 28	CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	May. 28	MT
CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	May. 28	CI
CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 23	CI
CUREVAC : Significant cash drain in the Q1	May. 23
Health Care Up as Vaccine Makers Gain - Health Care Roundup	May. 22	DJ
News Highlights : Top Company News of the Day - Wednesday at 5 PM ET	May. 22	DJ
CUREVAC : A missed opportunity	May. 02
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
CureVac Begins Early Stage Portion of Investigational Vaccine Trial	Apr. 24	MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	Apr. 24	MT
Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M	Apr. 24	MT
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza; Development in Collaboration with GSK	Apr. 24	CI
CureVac N.V. and the University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel Cancer Vaccines	Apr. 16	CI
CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers	Apr. 04	MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study	Apr. 04	MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study	Apr. 04	MT
CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK	Apr. 04	CI
CureVac Reports Positive Phase 2 Results for mRNA Covid Vaccines Developed With GSK	Jan. 05	MT
GSK, CureVac Plan Late-stage Study of COVID-19 mRNA Vaccine Candidates	Jan. 05	MT
Dpa-AFX Overview: COMPANIES from 27.12.2023 - 15:15	Dec. 27	DP

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

CUREVAC : Significant cash drain in the Q1

May 23, 2024 at 03:49 pm EDT